Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
825 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00457743 | A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Nov 13, 2009 | clinicaltrials |
| NCT01001936 | Study Evaluating SKI-606 in Subject With Solid Tumors | completed | Phase 1 | 28 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Oct 27, 2009 | clinicaltrials |
| NCT00143312 |
| Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants(VOSIFI) |
| completed |
| Phase 4 |
| 45 |
| PfizerINDUSTRY |
| 8 |
| Oct 6, 2009 |
| clinicaltrials |
| NCT00137423 | Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer | completed | Phase 2 | 107 | PfizerINDUSTRY | 7 | Sep 30, 2009 | clinicaltrials |
| NCT00075218 | A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) | completed | Phase 3 | 361 | PfizerINDUSTRY | 11 | Sep 28, 2009 | clinicaltrials |
| NCT00313768 | Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC | terminated | Phase 2 | 23 | PfizerINDUSTRY | 1 | Sep 28, 2009 | clinicaltrials |
| NCT00321308 | Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 36 | PfizerINDUSTRY | 3 | Sep 28, 2009 | clinicaltrials |
| NCT00137449 | Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor | completed | Phase 2 | 60 | PfizerINDUSTRY | 3 | Sep 15, 2009 | clinicaltrials |
| NCT00161642 | Study Evaluating CMD-193 in Advanced Malignant Solid Tumors | completed | Phase 1 | 54 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 10, 2009 | clinicaltrials |
| NCT00037583 | Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | completed | Phase 2 | 69 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00063219 | Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy | completed | Phase 2 | 48 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Aug 21, 2009 | clinicaltrials |
| NCT00063427 | Study Evaluating MAC-321 in Colorectal Cancer | completed | Phase 2 | 45 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00067548 | Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 44 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00072748 | Study Evaluating EKB-569 in Advanced Colorectal Cancer | completed | Phase 2 | 63 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00962767 | Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission | completed | Phase 3 | 168 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 20, 2009 | clinicaltrials |
| NCT00037804 | Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction | completed | Phase 1 | — | PfizerINDUSTRY | 1 | Aug 14, 2009 | clinicaltrials |
| NCT00195572 | Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer | completed | Phase 3 | 200 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Aug 13, 2009 | clinicaltrials |
| NCT00195585 | Study Evaluating Isovorin in Colon Cancer | completed | Phase 3 | 650 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Aug 13, 2009 | clinicaltrials |
| NCT00141791 | Study Evaluating Etanercept in Moderate to Severe Asthma | completed | Phase 2 | 120 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Aug 7, 2009 | clinicaltrials |
| NCT00304447 | Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia | completed | Phase 4 | 30 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Jul 29, 2009 | clinicaltrials |
| NCT00759837 | Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | completed | Phase 1 | 27 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 16, 2009 | clinicaltrials |
| NCT00444704 | Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females | completed | Phase 1 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 10, 2009 | clinicaltrials |
| NCT00174369 | MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 34 | PfizerINDUSTRY | 1 | Mar 17, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00043394 | CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer | completed | Phase 2 | 16 | PfizerINDUSTRY | 1 | Mar 12, 2009 | clinicaltrials |
| NCT00826436 | Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 in Japanese Postmenopausal Women | completed | — | 16 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 6, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00043420 | CPG 7909 in Patients With Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00070629 | CPG 7909 Injection in Non-Small Cell Lung Cancer | completed | Phase 2 | 116 | PfizerINDUSTRY | 3 | Feb 10, 2009 | clinicaltrials |
| NCT00070642 | CPG 7909 Injection in Melanoma | completed | Phase 2 | 184 | PfizerINDUSTRY | 0 | Feb 10, 2009 | clinicaltrials |
| NCT00174434 | Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer | completed | Phase 1 | 22 | PfizerINDUSTRY | 1 | Jan 27, 2009 | clinicaltrials |
| NCT00078000 | A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies. | completed | Phase 2 | 64 | PfizerINDUSTRY | 1 | Nov 26, 2008 | clinicaltrials |
| NCT00712504 | Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer | completed | Phase 1 | 49 | PfizerINDUSTRY | 1 | Nov 11, 2008 | clinicaltrials |
| NCT00091689 | Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions | completed | Phase 1 | — | PfizerINDUSTRY | 1 | Oct 27, 2008 | clinicaltrials |
| NCT00189332 | Use of 852A in Metastatic Cutaneous Melanoma. | completed | Phase 2 | 28 | PfizerINDUSTRY | 3 | Oct 27, 2008 | clinicaltrials |
| NCT00777530 | Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects | completed | Phase 1 | 48 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 23, 2008 | clinicaltrials |
| NCT00072852 | Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine | completed | Phase 2 | 134 | PfizerINDUSTRY | 5 | Oct 16, 2008 | clinicaltrials |
| NCT00092001 | Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 111 | PfizerINDUSTRY | 3 | Oct 16, 2008 | clinicaltrials |
| NCT00036283 | Chemoprevention of Oral Premalignant Lesions | completed | Phase 2 | 42 | PfizerINDUSTRY | 1 | Sep 29, 2008 | clinicaltrials |
| NCT00037180 | For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy | terminated | Phase 2 | 212 | PfizerINDUSTRY | 1 | Sep 29, 2008 | clinicaltrials |
| NCT00147485 | A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00056693 | Treatment With SU11248 in Patients With Neuroendocrine Tumors | completed | Phase 2 | 107 | PfizerINDUSTRY | 1 | Jul 21, 2008 | clinicaltrials |
| NCT00037544 | Study Evaluating ReFacto AF in Severe Hemophilia A | completed | Phase 3 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Apr 22, 2008 | clinicaltrials |
| NCT00635323 | Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma | completed | Phase 2 | 73 | PfizerINDUSTRY | 4 | Apr 7, 2008 | clinicaltrials |
| NCT00068952 | Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme | completed | Phase 3 | 118 | PfizerINDUSTRY | 13 | Apr 1, 2008 | clinicaltrials |
| NCT00087503 | Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy | completed | Phase 2 | 28 | PfizerINDUSTRY | 5 | Apr 1, 2008 | clinicaltrials |
| NCT00139711 | Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 138 | PfizerINDUSTRY | 1 | Apr 1, 2008 | clinicaltrials |
| NCT00140036 | Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV). | completed | Phase 4 | 137 | PfizerINDUSTRY | 2 | Mar 3, 2008 | clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials